{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:35:40Z","timestamp":1790130940349,"version":"4.0.1"},"reference-count":10,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"27","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2020,9,20]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> Immune checkpoint inhibitors (ICIs) are standard therapy in metastatic renal cell carcinoma (RCC). The safety and activity of the combination of ipilimumab and nivolumab in patients who have received prior ICI targeting the programmed death 1 (PD-1) pathway remains unknown. We evaluated ipilimumab and nivolumab in patients with metastatic RCC after prior treatment with anti\u2013PD-1 pathway\u2013targeted therapy. <\/jats:p><\/jats:sec><jats:sec><jats:title>PATIENTS AND METHODS<\/jats:title><jats:p> Patients with metastatic RCC who received prior anti\u2013PD-1 pathway-targeted therapy and subsequently received ipilimumab and nivolumab were reviewed. Objective response rate and progression-free survival per investigator assessment were recorded. Toxicity of ipilimumab and nivolumab was also assessed. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> Forty-five patients with metastatic RCC were included. All patients (100%) received prior ICIs targeting the PD-1 pathway. The median age was 62 years (range, 21-82 years). At a median follow-up of 12 months, the objective response rate to ipilimumab and nivolumab was 20%. The median progression-free survival while on ipilimumab and nivolumab was 4 months (range, 0.8-19 months). Immune-related adverse events (irAEs) of any grade with ipilimumab and nivolumab were recorded in 29 (64%) of the 45 patients; grade 3 irAEs were recorded in 6 (13%) of the 45 patients. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> Ipilimumab and nivolumab demonstrated antitumor activity with acceptable toxicity in patients with metastatic RCC who had prior treatment with checkpoint inhibition. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.19.03315","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T20:05:26Z","timestamp":1591214726000},"page":"3088-3094","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":89,"title":["Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors"],"prefix":"10.1200","volume":"38","author":[{"given":"Anita","family":"Gul","sequence":"first","affiliation":[{"name":"Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler F.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, New Haven, CT"},{"name":"Department of Medicine, Division of Hematology\/Oncology, University of California, San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene M.","family":"Mantia","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Georgetown Lombardi Comprehensive Cancer Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Stern","family":"Gatof","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Long","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly D.","family":"Allman","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe C.","family":"Ornstein","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Hammers","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"McDermott","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Atkins","sequence":"additional","affiliation":[{"name":"Georgetown Lombardi Comprehensive Cancer Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hurwitz","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23552"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.1.289"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/367354"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1985"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00662.x"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2035"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.19.03315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T06:51:59Z","timestamp":1653807119000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.19.03315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,20]]},"references-count":10,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2020,9,20]]}},"alternative-id":["10.1200\/JCO.19.03315"],"URL":"https:\/\/doi.org\/10.1200\/jco.19.03315","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,20]]},"assertion":[{"value":"2020-04-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}